NEW YORK (GenomeWeb News) – Agilent Technologies said this week that Erasmus Medical Center in Rotterdam, Netherlands, will use the firm's SureSelect XT Human All Exon target enrichment system along with the Agilent Bravo automated liquid-handling platform as part of the Erasmus Rucphen Family study to identify genetic risk factors for some complex genetic disorders. As part of the project, researchers are sequencing the exomes of 1,500 samples.
AB Sciex this week said that it has opened a new application and training center at its Singapore biomedical hub. It said the new center will serve researchers in Southeast Asia, Australia, New Zealand, Japan, and Korea, and it will complement the regional application support center the firm opened last year in Shanghai, China.
Roche said this week that its board of directors has proposed a 3 percent dividend increase for 2011 to CHF 6.80 ($7.39) per share. If the proposal is approved by shareholders, Roche said that 55 percent of its net income would be distributed to shareholders as dividends.
Warnex said that the Toronto Stock Exchange has agreed to extend the date of delisting of its common shares to the close of business on March 19. The firm said that it is exploring "various options" in light of the scheduled delisting. It also said that Persistence Capital Partners has agreed to extend the maturity date of the two outstanding convertible debentures of Warnex that it holds in the aggregate amount of C$1.4 million (US$1.4 million)to March 19.
Chronix Biomedical has opened a sequencing lab in Brookings, SD. The San Jose, Calif.-based firm said that the lab will offer sequencing services to academic and pharmaceutical researchers in support of their biomarker programs.
In Brief This Week is a Friday column containing news items that our readers may have missed during the week.